KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC Meeting Abstract
| Authors: | Saji, S.; Llombart Cussac, A.; Andre, F.; Robson, M. E.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Ahn, J. S.; Nanda, R.; Fan, L.; Mejia, J. A.; Karantza, V.; Bardia, A.; Rugo, H. S. |
| Abstract Title: | KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC |
| Meeting Title: | ESMO Asia Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2020 Nov 20-22 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-11-01 |
| Start Page: | S1268 |
| Language: | English |
| ACCESSION: | WOS:000600988900069 |
| DOI: | 10.1016/j.annonc.2020.10.088 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 68TiP -- Source: Wos |
